drugset / Trial / NCT00456261
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
Phase 2
Completed
110 enrolled
SCRI Development Innovations, LLC
Eli Lilly and Company · collabGenentech, Inc. · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This trial will look at 2 different drug combinations that have well known safety profiles and are known to be active against non small cell lung cancer and combine them with bevacizumab, an experimental drug that has shown effectiveness when added to other drug combinations for advanced non-small cell lung cancer. The primary objective in this study is to see how well this combination of drugs keeps the cancer from getting worse in this elderly population of non-small cell lung cancer patients.
Timeline
- Start
- 2007-03
- Primary completion
- 2010-02
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Gemcitabine | Small molecule | 1500 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |